Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer

Journal of Clinical Oncology

Volumn 20, Issue 23, 2002, Pages 4567-4573

  D'Amico, Anthony V ^a   Cote, Kerri ^a   Loffredo, Marian ^a   Renshaw, Andrew A ^a   Schultz, Delray ^a  

^a MILLERSVILLE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; GONADORELIN ANTAGONIST; PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; CANCER HORMONE THERAPY; CANCER SURVIVAL; CAUSE OF DEATH; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION BEAM; TREATMENT FAILURE;

AGED; DISEASE-FREE SURVIVAL; HUMANS; MALE; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; RISK ASSESSMENT; RISK FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0036895121     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.03.061     Document Type: Article

References (25)

1. Han M, Lai S, Partin AW, et al: Biochemical (PSA): Recurrence probability following radical retropubic prostatectomy for clinically localized prostate cancer. J Urol 165:149, 2001 (abstr 610)
2. Shipley WU, Thames HD, Sandler HM, et al: Radiation therapy for clinically localized prostate cancer: A multi-institutional pooled analysis. JAMA 281:1598-1604, 1999
3. D'Amico AV, Whittington R, Malkowicz SB, et al: Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280:969-974, 1998
4. Kattan MW, Easthan JA, Stapleton AMF, et al: A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 90:766-771, 1998
5. Albertsen PC, Hanley JA, Gleason DF, et al: Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 280:975-980, 1998
6. Pound CR, Partin AW, Eisenberger MA, et al: Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281:1591-1597, 1999
7. Lee WR, Hanks GE, Hanlon A: Increasing prostate-specific antigen profile following definitive radiation therapy for localized prostate cancer: Clinical observations. J Clin Oncol 15:230-238, 1997
8. Gleason DF and the Veterans Administration Cooperative Urological Research Group: Histologic grading and staging of prostatic carcinoma, in Tannenbaum M (ed): Urologic Pathology. Philadelphia, PA, Lea & Febiger, 1977, pp 171-187
9. Lee CT, Oesterling JE: Using prostate-specific antigen to eliminate the staging radionuclide bone scan. Urol Clin North Am 24:389-394, 1997
10. Beahrs OH, Henson DE, Hutter RVP: American Joint Committee on Cancer, Manual for Staging of Cancer (ed 4). Philadelphia, PA, Lippincott, 1992
11. Dearnaley D, Khoo V, Norman A, et al: Comparison of radiation side effects of conformal and conventional radiotherapy in prostate cancer: A randomized trial. Lancet 353:267-272, 1999
12. Cox JD, for the American Society for Therapeutic Radiology and Oncology Consensus Panel: Consensus statement: Guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 37:1035-1041, 1997
13. Neter J, Wasserman W, Kutner M (eds): Simultaneous inferences and other topic in regression analysis-1, in Applied Linear Regression Models. Homewood, IL, Richard D. Irwin, Inc, 1983, pp 150-153
14. Sandler HM, Dunn RL, McLaughlin PW, et al: Overall survival after prostate-specific-antigen-detected recurrence following conformal radiation therapy. Int J Radiat Oncol Biol Phys 48:629-633, 2000
15. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
16. Gaynor JJ, Feur FJ, Tan CC, et al: On the use of cause-specific failure and conditional failure probabilities: Examples from clinical oncology data. J Am Stat Assoc 88:400-409, 1993
17. Kattan MW, Wheeler TM, Scardino PT: Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol 17:1499-1507, 1999
18. D'Amico AV, Whittington R, Malkowicz SB, et al: Utilizing predictions of early prostate-specific antigen failure to optimize patient selection for adjuvant therapy trials. J Clin Oncol 18:3240-3246, 2000
19. Bolla M, Gonsalez D, Warde P, et al: Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 337:295-300, 1997
20. Patel A, Dorey F, Franklin J, et al: Recurrence patterns after radical retropubic prostatectomy: Clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. J Urol 158:1441-1445, 1997
21. Roberts SG, Blute ML, Bergstralh EJ, et al: PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer. Mayo Clin Proc 76:576-581, 2001
22. Sartor CI, Strawderman MH, Lin XH, et al: Rate of PSA rise predicts metastatic versus local recurrence after definitive radiotherapy. Int J Radiat Oncol Biol Phys 38:941-947, 1997
23. Immediate versus deferred treatment for advanced prostatic cancer: Initial results of the Medical Research Council Trial - The Medical Research Council Prostate Cancer Working Party Investigators Group. Br J Urol 79:235-246, 1997
24. Messing EM, Manola J, Sarosdy M, et al: Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 341:1781-1788, 1999
25. Prentice RL: Surrogate endpoints in clinical trials: Definition and operational criteria. Stat Med 8:431-440, 1989